Bionano Genomics Reports Strong Q3 2025 Results

Bionano Genomics ( (BNGO) ) has released its Q3 earnings. Here is a breakdown of the information Bionano Genomics presented to its investors.

Bionano Genomics, Inc., a company specializing in genome analysis solutions, focuses on optical genome mapping (OGM) to assist researchers and clinicians in addressing complex genetic questions. In its latest earnings report, Bionano Genomics highlighted a strategic shift towards enhancing consumables and software utilization, which has contributed to a 21% increase in total revenue for the third quarter of 2025 compared to the same period in 2024. The company also reported a significant improvement in gross margins and a reduction in operating expenses.

Key financial metrics from the third quarter include a total revenue of $7.4 million, a 15% increase in consumables and software revenues, and a 7% rise in nanochannel array flowcell sales. Bionano’s installed base of OGM systems grew by 4%, and the company achieved a gross margin of 46%, a substantial improvement from the previous year’s negative margin. Operating expenses were reduced by 66%, reflecting disciplined financial management.

The company also completed a public stock offering, raising $10 million, and showcased its global momentum through various studies and presentations. Bionano’s OGM technology continues to gain traction, with 97 peer-reviewed publications in the third quarter, underscoring its growing acceptance in the scientific community.

Looking ahead, Bionano Genomics maintains its revenue guidance for 2025, anticipating full-year revenue between $26.0 to $30.0 million and expecting new OGM system installations to exceed previous expectations. The company remains focused on expanding its market presence and driving the adoption of its OGM solutions.